WO2004020468A3 - Interferon beta-like molecules for treatment of cancer - Google Patents
Interferon beta-like molecules for treatment of cancer Download PDFInfo
- Publication number
- WO2004020468A3 WO2004020468A3 PCT/DK2003/000554 DK0300554W WO2004020468A3 WO 2004020468 A3 WO2004020468 A3 WO 2004020468A3 DK 0300554 W DK0300554 W DK 0300554W WO 2004020468 A3 WO2004020468 A3 WO 2004020468A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- interferon
- ifnb
- mammal
- life
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003254641A AU2003254641A1 (en) | 2002-08-28 | 2003-08-25 | Interferon beta-like molecules for treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40718802P | 2002-08-28 | 2002-08-28 | |
US60/407,188 | 2002-08-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004020468A2 WO2004020468A2 (en) | 2004-03-11 |
WO2004020468A3 true WO2004020468A3 (en) | 2004-06-10 |
Family
ID=31978437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2003/000554 WO2004020468A2 (en) | 2002-08-28 | 2003-08-25 | Interferon beta-like molecules for treatment of cancer |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003254641A1 (en) |
WO (1) | WO2004020468A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
KR101238517B1 (en) | 2002-12-26 | 2013-02-28 | 마운틴 뷰 파마슈티컬즈, 인크. | Polymer conjugates of interferon-beta with enhanced biological potency |
AU2004220525B2 (en) | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
KR20070034465A (en) | 2004-03-12 | 2007-03-28 | 바스진 테라퓨틱스, 인크. | Polypeptide Compounds for Inhibiting Angiogenesis and Tumor Growth |
EP2287194B1 (en) | 2004-03-12 | 2016-10-26 | Vasgene Therapeutics, Inc. | Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth |
EP1799713B1 (en) * | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
US20120082647A1 (en) * | 2010-10-01 | 2012-04-05 | Baker Darren P | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
MY168902A (en) | 2011-10-01 | 2018-12-04 | Glytech Inc | Glycosylated polypeptide and pharmaceutical composition containing same |
DK2982686T3 (en) * | 2013-03-29 | 2018-10-08 | Glytech Inc | POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED |
CN107773753B (en) * | 2016-12-05 | 2020-12-22 | 四川好医生攀西药业有限责任公司 | Medicine containing periplaneta americana and bleomycin and application thereof |
WO2021221470A1 (en) * | 2020-04-29 | 2021-11-04 | (주) 제노팜 | Recombinant protein having fused interferon-beta mutein and antibody, and pharmaceutical composition comprising same |
CN115989239A (en) * | 2020-04-29 | 2023-04-18 | 瑷备恩有限公司 | Human interferon beta variants with double mutations and methods for improving the stability of human interferon beta variants |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05271095A (en) * | 1991-05-30 | 1993-10-19 | Chugai Pharmaceut Co Ltd | Anticancer agent |
WO1998048018A1 (en) * | 1997-04-23 | 1998-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Recombinant human beta interferon with enhanced solubility |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
WO1999055377A2 (en) * | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
JP2000109434A (en) * | 1998-08-06 | 2000-04-18 | Toray Ind Inc | Inhibition of cell growth and cell growth inhibitor |
WO2000023114A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Polymer conjugates of interferon beta- 1a and their uses |
WO2000023472A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
WO2000068387A2 (en) * | 1999-05-12 | 2000-11-16 | Xencor, Inc. | Nucleic acids and proteins with interferon-beta activity |
WO2001015736A2 (en) * | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
WO2002036628A2 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | New multimeric interferon beta polypeptides |
WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
WO2002072019A2 (en) * | 2001-03-13 | 2002-09-19 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
WO2002074806A2 (en) * | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
-
2003
- 2003-08-25 AU AU2003254641A patent/AU2003254641A1/en not_active Abandoned
- 2003-08-25 WO PCT/DK2003/000554 patent/WO2004020468A2/en not_active Application Discontinuation
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05271095A (en) * | 1991-05-30 | 1993-10-19 | Chugai Pharmaceut Co Ltd | Anticancer agent |
WO1998048018A1 (en) * | 1997-04-23 | 1998-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Recombinant human beta interferon with enhanced solubility |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
WO1999055377A2 (en) * | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
JP2000109434A (en) * | 1998-08-06 | 2000-04-18 | Toray Ind Inc | Inhibition of cell growth and cell growth inhibitor |
WO2000023472A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
WO2000023114A2 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Polymer conjugates of interferon beta- 1a and their uses |
WO2000068387A2 (en) * | 1999-05-12 | 2000-11-16 | Xencor, Inc. | Nucleic acids and proteins with interferon-beta activity |
WO2001015736A2 (en) * | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
WO2002036628A2 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | New multimeric interferon beta polypeptides |
WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
WO2002074806A2 (en) * | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
WO2002072019A2 (en) * | 2001-03-13 | 2002-09-19 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
Non-Patent Citations (4)
Title |
---|
FRANCESCO RECCHIA ET AL: "Advanced Carcinoma of the Pancreas", AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 3, 1998, pages 275 - 278, XP002263696 * |
LAURA RUNKEL ET AL: "Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-Beta (IFN-Beta)", PHARMACEUTICAL RESEARCH, vol. 15, no. 4, 1998, pages 641 - 649, XP002271902 * |
PATENT ABSTRACTS OF JAPAN vol. 018, no. 046 (C - 1157) 25 January 1994 (1994-01-25) * |
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 07 29 September 2000 (2000-09-29) * |
Also Published As
Publication number | Publication date |
---|---|
WO2004020468A2 (en) | 2004-03-11 |
AU2003254641A8 (en) | 2004-03-19 |
AU2003254641A1 (en) | 2004-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004020468A3 (en) | Interferon beta-like molecules for treatment of cancer | |
WO2007047291A3 (en) | Anti-glypican-3 antibody | |
BG104871A (en) | Polyol-ifn-beta conjugates | |
GR3032511T3 (en) | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer. | |
MY112405A (en) | Method of tumer treatment. | |
AU2001287639A1 (en) | Trp8, trp9 and trp10, markers for cancer | |
EA200100289A1 (en) | METHOD OF ADMINISTRATION OF INSULINOTROPIC PEPTIDES | |
NO993654L (en) | Kit for inhibiting cancer growth, comprising a chemotherapeutic agent and a benzimidazole and optionally an enhancer | |
WO2003039458A3 (en) | TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α | |
HK1040983A1 (en) | Quinones for treatment of diseases. | |
WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
WO2001018046A3 (en) | Ovarian tumor sequences and methods of use therefor | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
IL126152A0 (en) | Recombinant adenoviral vectors for human tumor gene therapy | |
EP1601756A4 (en) | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes | |
IL114382A (en) | Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament | |
HUT43495A (en) | Process for production and compound for treating of cancer and beningn tumor | |
AU6969098A (en) | 1,2,4-benzotriazine oxides formulations | |
WO2002076394A3 (en) | Enzyme-based anti-cancer compositions and methods | |
MX9805299A (en) | Novel polynucleotides panc1a and panc1b associated with pancreatic cancer. | |
AR023726A1 (en) | THERAPY WITH GCH FOR THE TREATMENT OF CANCER OF MAMA | |
WO2000004153A3 (en) | Repression of cell transformation with human pea3 | |
WO2000020589A3 (en) | PTANs: TESTIS SPECIFIC PROTEINS EXPRESSED IN PROSTATE CANCER | |
WO1998023299A3 (en) | Radiolabeled dna oligonucleotide, method of preparation and therapeutic uses thereof | |
WO2003086298A3 (en) | Use of interleukin-19 to treat ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |